TA-606

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528418

CAS#: 190602-72-3

Description: TA-606, also known as TA-606 free, is an angiotensin type 1 receptor antagonist potentially for the treatment of hypertension. TA-606 was immediately converted to its active form, 606A, after oral administration, and it demonstrated potent inhibition of the Ang II-induced pressor response in conscious normotensive dogs. It also had a potent hypotensive effect in conscious 2K,1C-renal hypertensive dogs. These effects of TA-606 were 32 and 30 times more potent than those of losartan, respectively. In addition, EXP3174, an active metabolite of losartan, but not 606A showed an orthostatic hypotensive effect in the rat tilting model.

Chemical Structure

img
TA-606
CAS# 190602-72-3
Instruction

Theoretical Analysis

MedKoo Cat#: 528418
Name: TA-606
CAS#: 190602-72-3
Chemical Formula: C33H40ClN7O6
Exact Mass: 0.00
Molecular Weight: 666.176
Elemental Analysis: C, 59.50; H, 6.05; Cl, 5.32; N, 14.72; O, 14.41

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 190602-72-3 (HCl)   190602-73-4 (free)  

Synonym: TA-606, TA 606, TA606, TA-606 free

IUPAC/Chemical Name: (((pentan-3-yloxy)carbonyl)oxy)methyl 3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-5-acetyl-2-propyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-4-carboxylate hydrochloride

InChi Key: GEUFBLVOYZGVMX-UHFFFAOYSA-N

InChi Code: InChI=1S/C33H39N7O6.ClH/c1-5-10-28-34-27-17-18-39(21(4)41)30(32(42)44-20-45-33(43)46-24(6-2)7-3)29(27)40(28)19-22-13-15-23(16-14-22)25-11-8-9-12-26(25)31-35-37-38-36-31;/h8-9,11-16,24,30H,5-7,10,17-20H2,1-4H3,(H,35,36,37,38);1H

SMILES Code: CC(N1C(C(OCOC(OC(CC)CC)=O)=O)C2=C(N=C(CCC)N2CC3=CC=C(C4=C(C5=NN=NN5)C=CC=C4)C=C3)CC1)=O.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 666.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother. 2009 Dec;63(10):754-61. doi: 10.1016/j.biopha.2009.02.006. PubMed PMID: 19304450.

2: Kashimura T, Hayashi M, Kodama M, Nakazawa M, Abe S, Yoshida T, Tachikawa H, Hanawa H, Kato K, Watanabe K, Aizawa Y. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J. 2003 Sep;44(5):735-44. PubMed PMID: 14587655.

3: Ishizaka N, Nakao A, Ohishi N, Suzuki M, Aizawa T, Taguchi J, Nagai R, Shimizu T, Ohno M. Increased leukotriene A(4) hydrolase expression in the heart of angiotensin II-induced hypertensive rat. FEBS Lett. 1999 Dec 10;463(1-2):155-9. PubMed PMID: 10601658.

4: Hashimoto Y, Ohashi R, Minami K, Narita H. Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol. 1999 Sep;81(1):63-72. PubMed PMID: 10580372.

5: Hashimoto Y, Yabana H, Narita H. Diverse effects of AT1 receptor antagonists on normal blood pressure and regulatory system. Hypertens Res. 1999 Jul;22(2):121-7. PubMed PMID: 10487328.

6: Uehara Y, Hirawa N, Kawabata Y, Numabe A, Gomi T, Ikeda T, Omata M. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus. Am J Hypertens. 1999 Jan;12(1 Pt 1):21-7. PubMed PMID: 10075380.

7: Hashimoto Y, Ohashi R, Kurosawa Y, Minami K, Kaji H, Hayashida K, Narita H, Murata S. Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. J Cardiovasc Pharmacol. 1998 Apr;31(4):568-75. PubMed PMID: 9554806.